NEFL and myeloid sarcoma: However, a major clinical disadvantage of using serum NfL levels as a biomarker is that the levels do not distinguish MS from other neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease, which also exhibit elevated NfL serum and CSF levels [185,186,187].